1 results match your criteria: "National Clinical Research Center of Hematologic Diseases[Affiliation]"
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.
Invest New Drugs
June 2024
Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, No 188, Shizi Street, Suzhou, Jiangsu, 215006, China.
Article Synopsis
- Blinatumomab shows effectiveness in treating B-cell acute lymphoblastic leukemia (B-ALL) but has limited real-world data, which this study aimed to address by analyzing its impact on Chinese patients with newly diagnosed (ND) and relapsed/refractory (R/R) B-ALL.
- The study included 96 B-ALL patients treated with at least one dose of blinatumomab, reporting significant outcomes such as a 100% complete remission (CR) rate for ND patients and a 50% CR rate for R/R patients, along with high rates of minimal residual disease (MRD) negativity.
- Overall, blinatumomab demonstrated a favorable safety profile, with only 12